Abstract
Rituximab is a chimeric monoclonal antibody targeted against CD20 which is a surface antigen present on B cells. In last 20 years Rituximab becomes a standard of care for treatment of several rare diseases like Chronic lymphocytic leukemia, Folicular limphoma and Diffuse large B-cell lymphoma. It is expected that the entry of biosimilars on the market will lead to a reduction in the cost of drug therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
